EBS News and Press, Emergent Biosolutions Inc. From 07/08/20

( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...

Emergent BioSolutions (NYSE: EBS ) has closed a five-year agreement with Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals for large-scale drug substance manufacturing for J&J's SARS-CoV-2 vaccine, Ad26.COV2-S. More news on: Emergent BioSolutions Inc., Johnson & Joh...

Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million For the remaining three years beginning in 2023, Emergent will provide a...

Shares of  Emergent Biosolutions (NYSE: EBS) and  Regeneron (NASDAQ: REGN) have risen sharply in 2020 thanks to potential coronavirus drugs in development, but that's where their similarities end. Is Emergent, a company with government contracts to produce vaccines for other drug...

Shares of biopharmaceutical company Emergent BioSolutions   (NYSE: EBS) gained 46.6% in the first half of 2020 (January to June), according to data from S&P Global Market Intelligence . The S&P 500 returned negative 3.1% over the period. In 2020, the stock is up 55.9% through ...

If you had bought Novavax   (NASDAQ: NVAX) stock at the beginning of the year, you would be a happy investor right now. Shares of this biotech company have skyrocketed by almost 2,000% year to date, a rare feat even within the volatile biotech industry. Novavax has been able to achieve th...

More than a dozen companies are now in some way involved in the hunt for a vaccine for COVID-19. These include household names, like Merck , and less famous ones, like Dynavax . Considering how crowded this race is, it is difficult to know which company will end up benefiting the most from its...

Last week, the top-performing biotech stocks had something in common and by now you can probably guess exactly what that was. You got it. They both delivered positive press releases regarding their respective coronavirus vaccine candidates. Data source: Yahoo! Finance. Continue reading

Vaxart (NASDAQ: VXRT) and VBI Vaccines (NASDAQ: VBIV) are both young vaccine companies seeking to develop a vaccine for COVID-19. Neither company is profitable, but both stocks have experienced triple-digit growth in the last three months. Future stock growth stemming from advances in v...

Vaccine startup Vaxart (NASDAQ: VXRT) announced Thursday morning that it was initiating a memorandum of understanding with Attwill Medical Solutions Sterilflow. The latter company will produce components for Vaxart's COVID-19 vaccine candidate currently in preclinical development, and Vaxart...